Abstract Number: 0999 • ACR Convergence 2020
CXCL13 Is a Key Driver for Migration and Differentiation of Regulatory B Cells
Background/Purpose: Human regulatory B cells still need to be characterized. Given the absence of phenotypical definition, a functional definition based on their ability to secrete…Abstract Number: 1015 • ACR Convergence 2020
The Prevalence and Risk Factors for Liver Fibrosis Among Rheumatoid Arthritis (RA) Patients on Disease-Modifying Anti-rheumatic Drugs (DMARDs)
Background/Purpose: Majority of DMARDs, including methotrexate (MTX), leflunomide (LEF) and sulfasalazine (SSZ) arebelieved to be hepatotoxic, causing liver fibrosis. However, the clinical findings were inconsistent.…Abstract Number: 1186 • ACR Convergence 2020
Red Cell Distribution Width and Absolute Lymphocyte Count Associate with Biomarkers of Inflammation and Subsequent Mortality in Rheumatoid Arthritis
Background/Purpose: Peripheral blood red cell distribution width (RDW) and absolute lymphocyte count (ALC) are associated with aging, cardiovascular disease (CVD), and mortality in the general…Abstract Number: 1202 • ACR Convergence 2020
Cannabis Use Assessment and Its Impact on Pain in Rheumatic Diseases: A Systematic Review and Meta-analysis
Background/Purpose: Despite classic analgesic or effective treatments in rheumatic diseases, such as synthetic Disease Modifying Anti-Rheumatic Drugs in rheumatoid arthritis (RA), patients remain in pain…Abstract Number: 1218 • ACR Convergence 2020
Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, Health-related Quality of Life, and Fatigue in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate
Background/Purpose: In the FINCH 1 study, filgotinib (FIL)—an oral, potent, selective JAK1 inhibitor—plus methotrexate (MTX) provided significant improvements in signs and symptoms of rheumatoid arthritis…Abstract Number: 1236 • ACR Convergence 2020
Association Between Change in Health Assessment Questionnaire Disability Index and Treatment Response in Patients with Rheumatoid Arthritis in Tocilizumab Clinical Trials
Background/Purpose: The efficacy and safety of intravenous (IV) and subcutaneous (SC) tocilizumab (TCZ) in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and as monotherapy…Abstract Number: 1460 • ACR Convergence 2020
“Can I Help You with Your RA Today?”: A Pilot Study on the User Experience with a Voice-Enabled Smartphone App to Virtually Monitor Disease Activity and Collect ePROs in Rheumatoid Arthritis
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic disease that involves frequent patient-provider interaction and self-monitoring, both integral to successful disease management. We developed a novel…Abstract Number: 1536 • ACR Convergence 2020
Ultrasound as an Imaging Biomarker of Early Response to Tocilizumab and Methotrexate in Early Rheumatoid Arthritis, TOVERA – a Longitudinal Study
Background/Purpose: The combination of methotrexate (MTX) and tocilizumab (TCZ) has been proven to be superior to MTX alone in early rheumatoid arthritis (RA)1 and was…Abstract Number: 1599 • ACR Convergence 2020
Workflows for Collecting and Using Patient-reported Outcomes Across Rheumatology Practices
Background/Purpose: The use of patient reported outcomes (PROs) during rheumatology visits may facilitate shared decision making and encourage patients to share their health goals. However,…Abstract Number: 1721 • ACR Convergence 2020
Increasing Autoantibody Positivity During Pre-RA Is Associated with the Imminent Development of Classifiable RA
Background/Purpose: Autoantibodies including rheumatoid factor (RF) and antibodies to citrullinated protein antigens (ACPA) may be elevated during a period that can be termed ‘Pre-RA’. In…Abstract Number: 1737 • ACR Convergence 2020
What Influences Fatigue Improvement in Rheumatoid Arthritis? A Prospective Cohort Study
Background/Purpose: Fatigue is a common and debilitating complication in patients with rheumatoid arthritis (RA). Its mechanism is not fully elucidated, and when persistent is often…Abstract Number: 1755 • ACR Convergence 2020
Body Mass Index Trajectory and Variability in Rheumatoid Arthritis
Background/Purpose: Past studies have examined associations between BMI and disease activity [1, 2, 3], but few studies have characterized BMI trajectory over the disease course…Abstract Number: 1848 • ACR Convergence 2020
Identification of Native and Citrullinated Autoantibodies to Psoriasis Related-antigen PsoP27 in Synovial Fluids of Patients with Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory joint disease with no serological biomarkers, hence diagnosis is based on clinical evaluation alone. PsA is closely associated…Abstract Number: 1997 • ACR Convergence 2020
Immunogenicity of Adjuvanted Herpes Zoster Subunit Vaccine in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors and Controls: Preliminary Results
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of contracting herpes zoster (HZ) and treatment with JAnus Kinase inhibitors (JAKi) further adds on…Abstract Number: 2044 • ACR Convergence 2020
Complex, Dynamic Attributes of Antigen-specific T Cells in Rheumatoid Arthritis
Background/Purpose: CD4+ T cells are implicated in the pathogenesis of rheumatoid arthritis (RA) due to strong genetic association with HLA class II alleles, the presence…
- « Previous Page
- 1
- …
- 134
- 135
- 136
- 137
- 138
- …
- 188
- Next Page »